Sort

Search

01/01/2025 Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial
Palmerini, E, Pousa, AL, Grignani, G, Redondo, A, Hindi, N, Provenzano, S, Sebio, A, Martin, JAL, Valverde, C, Trufero, JM, Gutierrez, A, de Alava, E, Gomez, MPA, D'Ambrosio, L, Collini, P, Bazzocchi, A, Moura, DS, Ibrahim, T, Stacchiotti, S, Broto, JM. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. CANCER. 2025; 131(1)DOI:10.1002/cncr.35628. PMID:39540661. IF:5.100(Q1/3D).
01/01/2025 Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse
Martinez-Recio, S, Molina-Pérez, MA, Muñoz-Couselo, E, Sevillano-Tripero, AR, Aya, F, Arance, A, Orrillo, M, Martin-Liberal, J, Fernandez-Morales, L, Lesta, R, Quindós-Varela, M, Nieva, M, Vidal, J, Martinez-Perez, D, Barba, A, Majem, M. Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse. Cancers. 2025; 17(1)DOI:10.3390/cancers17010143. PMID:39796770. IF:4.400(Q2/3D).
01/01/2025 Quality of Life and Patient-Reported Outcomes in Patients With Osteosarcoma: A Systematic Review
Sebio, A, Berger, C, Tabone, MD, Fernandez, N, Tardy, F, Grootenhuis, M, Palmerini, E, Gaspar, N, van de Sande, M, Haveman, LM. Quality of Life and Patient-Reported Outcomes in Patients With Osteosarcoma: A Systematic Review. EUROPEAN JOURNAL OF CANCER CARE. 2025; 2025(1)DOI:10.1155/ecc/5802523. PMID:. IF:1.900(Q2/4D).
01/01/2025 A Targeted Nanotoxin Inhibits Colorectal Cancer Growth Through Local Tumor Pyroptosis and Eosinophil Infiltration and Degranulation
Carrasco-Díaz, LM, Gallardo, A, Voltà-Durán, E, Virgili, AC, Paez, D, Villaverde, A, Vazquez, E, Alamo, P, Unzueta, U, Casanova, I, Mangues, R, Alba-Castellon, L. A Targeted Nanotoxin Inhibits Colorectal Cancer Growth Through Local Tumor Pyroptosis and Eosinophil Infiltration and Degranulation. International Journal of Nanomedicine. 2025; 20DOI:10.2147/IJN.S499192. PMID:40034221. IF:6.500(Q1/1D).